The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Analyzing first fecal transplant death: Donor stool wasn’t tested for rare E. coli strain

| | November 6, 2019

This spring, a 73-year-old man with a rare blood condition became the first person to die from drug-resistant bacteria found in a fecal transplant. New details about that unprecedented incident emerged on [October 30].

The man was a participant in a clinical trial run at Massachusetts General Hospital and received fecal transplant capsules made in November with fecal material from one stool donor, according to a paper published [October 30] in the New England Journal of Medicine. Tests after the man’s death revealed that material contained a rare type of E. coli bacteria.

MGH scientists started screening for those kinds of bacteria in January. However, the hospital did not test capsules they’d already produced, researchers disclosed.

Related article:  Can we figure out how to get new drugs to the market faster?

Twenty-one other people also received capsules made with material from the same donor, the NEJM paper said. One other person reported serious side effects, but recovered; several others tested positive for the resistant bacteria but weren’t made sick.

The paper’s publication comes just days before the FDA will hold a Nov. 4 meeting about the safety and regulation of fecal transplants.

Read full, original post: Massachusetts General Hospital oversaw trial that led to the first death from a fecal transplant, a new paper shows

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend